biostudies-literatureIgnatius EHHHS | National Institutes of HealthNIAID NIH HHSParatek Pharmaceuticals Ince0038124https://www.ebi.ac.uk/biostudies/studies/S-EPMC11288010biostudies-literatureUnknown9(7)Treatment outcomes for <i>Mycobacteroides abscessus</i> (<i>Mab</i>, also known as <i>Mycobacterium abscessus</i>) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating <i>Mab</i> disease is challenging due to its high baseline antibiotic resistance, initial requirement for intravenous therapy, and poor medication tolerance. Omadacycline, a new tetracycline, is active against <i>Mab</i>. Since any new antibiotic effective against <i>Mab</i> is expected to be used in combination with other antibiotics, we evaluated the efficacy of two triple-drug combinations comprising omadacycline, omadacycline + amikacin + imipenem, and omadacycline + clofazimine + linezolid against two contemporary <i>Mab</i> clinical isolates in a mouse model ofmSphereEfficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of <i>M. abscessus</i> lung disease.PMC11288010K23 AI159145Belz DCLippincott CKLamichhane GSerio AWRimal BPanthi CMIgnatius EHDeck DHfalseEfficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of <i>M. abscessus</i> lung disease.Treatment outcomes for <i>Mycobacteroides abscessus</i> (<i>Mab</i>, also known as <i>Mycobacterium abscessus</i>) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating <i>Mab</i> disease is challenging due to its high baseline antibiotic resistance, initial requirement for intravenous therapy, and poor medication tolerance. Omadacycline, a new tetracycline, is active against <i>Mab</i>. Since any new antibiotic effective against <i>Mab</i> is expected to be used in combination with other antibiotics, we evaluated the efficacy of two triple-drug combinations comprising omadacycline, omadacycline + amikacin + imipenem, and omadacycline + clofazimine + linezolid against two contemporary <i>Mab</i> clinical isolates in a mouse model of2024-01-01T00:00:00Z2024 Jul2026-06-02T09:19:24.096Z2026-04-16T03:13:16.086ZS-EPMC112880103898007110.1128/msphere.00381-24